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http:WHAT THIS PAPER ADDS
Lower extremity (LE) lymphedema is common and highly morbid, but a major knowledge gap exists in the
evidence deﬁning optimal treatment strategies. Pneumatic compression devices (PCDs) represent one poten-
tially beneﬁcial component of an effective multimodality approach to LE lymphedema. This study represents the
largest study of PCD treatment outcomes in LE patients. These data demonstrate that use of an advanced PCD
(APCD) is associated with signiﬁcant limb volume reduction, which was associated with improvement in quality
of life and no signiﬁcant adverse effects. The study provides conﬁdence that APCD use may beneﬁcially inﬂuence
treatment outcomes for patients with LE lymphedema.Objectives: Examine the effectiveness of an advanced pneumatic compression device (APCD) in reducing limb
volume (LV), and to evaluate clinician and patient-reported outcomes.
Design: Device registry study.
Materials and methods: Data were collected prospectively for 196 lower extremity lymphedema patients
prescribed an APCD. Baseline and post-treatment LVs were calculated and clinical outcomes (skin changes, pain,
and function) were assessed. Patient-reported outcomes and satisfaction utilizing a pre- and post-treatment
survey were also evaluated.
Results: 90% of APCD-treated patients experienced a signiﬁcant reduction in LV with 35% enjoying a reduction
>10%. Mean LV reduction was 1,150 mL or 8% (p < .0001). Greater baseline LV and BMI were strong predictors
of LV reduction (p < .0001). Clinician assessment indicated that the majority of patients experienced
improvement in skin ﬁbrosis and function. Patient-reported outcomes showed a signiﬁcant increase in ability to
control lymphedema through APCD treatment, with an increase in function and a reduction in the interference of
pain. 66% were “very satisﬁed” with the APCD treatment.
Conclusion: APCD use is associated with consistent reductions in LV, with favorable patient-reported outcomes.
Results demonstrate that reduction in LV and pain, combined with functional improvement and patient
satisfaction can be achieved, providing tangible beneﬁt for lower extremity patients.
 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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exact prevalence that remains unknown.1 The morbidity of
lymphedema is considerable. Most physicians focus on
reducing limb swelling, because the underlying disease is
generally not amenable to cure.2
Current strategies to improve lymphedema outcomes use
methods to increase lymph transport from the limb. The
standard of care, referred to as “complete decongestiveresponding author. S. Muluk, Temple University School of Medicine,
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//dx.doi.org/10.1016/j.ejvs.2013.07.012therapy” (CDT), includes skin care, manual lymphatic
drainage (MLD), compression bandaging, compression gar-
ments, and selected use of pneumatic compression devices
(PCDs).2e4 The optimal strategy has not been deﬁned from
randomized trials but rather from case series and ap-
proaches that apply simpler to more stringent compressive
strategies. Although robust comparative effectiveness data
are lacking, CDT is widely considered to represent the
standard of care.2
PCDs are frequently used to treat chronic lymphedema.
Postulated mechanisms of PCD efﬁcacy include simulating
the calf muscle pump, decreased capillary ﬁltration, and
reduced venous reﬂux.5 Use of PCDs is attractive because it
allows patients to continue therapy at home, outside the
clinic or hospital setting. Although PCD therapy requires the
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term reductions in use of healthcare services. The major-
ity of publications on PCD efﬁcacy have evaluated device
impact in individuals with upper extremity (UE) breast
cancer-related lymphedema (BCRL).5e16 The evidence base
for patients with LE lymphedema is limited by a paucity of
published data.
Commercially available PCDs include simple single
chamber devices providing non-calibrated, non-gradient
static compression to the entire limb. PCDs within the next
category have multiple chambers (typically 3e10) that
provide sequential treatment; may or may not provide
gradient pressure; and provide limited adjustability. The
advanced PCDs (APCDs) include “new generation” tech-
nology that provides calibrated, gradient sequential inﬂa-
tion with additional features enabling custom treatment to
address individual patient needs. Some newer devices
include garments that treat the core body areas (abdomen
and/or chest), and the pressure proﬁles and treatment
areas can be easily adjusted. Most PCDs were designed to
impact the venous system and therefore incorporate
treatment pressures and sequencing intended to mobilize
ﬂuid into the limb vasculature. These devices can best be
described as applying a “squeeze and hold” treatment.
Some newer APCDs have been designed to speciﬁcally
impact the lymphatic system, utilizing lower pressure pro-
ﬁles and treatment sequences intended to simulate manual
lymphatic treatment techniques.17
The APCD utilized in the current study is the Flexitouch
system (Tactile Systems Technology, Inc., Minneapolis, MN).
This APCD was designed to impact the lymphatic system
and mimic MLD by utilizing brief applications of dynamic
pressure to apply a gentle stretch against the skin to
stimulate lymphatic capillaries. The device is intended for
home use during the self-management phase of CDT. Near
infrared-imaging has shown systemic stimulation of the
lymphatic system, with increased lymphatic propulsion
rates.18 The programmable controller, which offers several
treatment programs to address LE swelling, produces a
gentle, wave-like application of pressure as the chambers
sequentially inﬂate and deﬂate. This dynamic pressure is
designed to move stagnant lymphatic ﬂuid from the distal
swollen limb toward the trunk.
LE lymphedema can adversely affect quality of life
(QOL).19 Treatment has traditionally focused on objective
outcomes (e.g., limb volume). As all lymphedema treat-
ments mandate signiﬁcant commitment from patients, it is
essential to assess patient-reported outcomes and satis-
faction in addition to objective measures.
The primary purpose of this study was to examine the
effectiveness of the Flexitouch system APCD on limb vol-
ume (LV) reduction in the treatment of LE lymphedema.
Secondary objectives were to compare pre- and post-
treatment patient-reported outcomes and to examine
clinician-reported outcomes after treatment. Sub-analyses
identiﬁed factors that may predict treatment responders.
We analyzed data from a prospectively collected data-
base of patients who were prescribed this APCDtreatment. This analysis evaluated LV, clinician-reported
outcomes, and patient-reported parameters. This device
outcomes registry was created because of a unique
mandate by a subset of third-party payers which requires
that certain PCDs be rented initially in order to evaluate
effectiveness prior to purchase. The study population
comprised patients who participated in this rental-
reauthorization process. The data represent “real world”
device experience.METHOD
From January 2009 to May 2012, 290 LE lymphedema pa-
tients received the APCD under a “rental-with-reauthoriza-
tion process” as required by a third-party payer. After a pre-
speciﬁed rental period, the patient was reassessed by the
referring clinician. This process required that both pre- and
post-APCD treatment limb measurements be obtained, and
key clinical measurements (e.g., skin changes and function)
be reported to the third-party payer. To be considered for
this program, patient’s stage of lymphedema had to be at
least Stage II based on payer criteria. To meet the study
entrance criteria, the patients were required to have a
signed consent authorizing their data to be used for
research purposes, pre- and post-treatment limb measure-
ments and a completed clinical assessment. Ninety-four
patients were excluded because of non-provision of
research consent (n ¼ 34) or missing data (n ¼ 60). One-
hundred and ninety-six patients met the entrance criteria
and were included. The Western Institutional Review Board
approved this study (No.1133766).
The follow-up clinical assessment was completed
approximately 60  27 days (range 17e242; median 55.5)
after the baseline measurements and initial APCD treat-
ment. Chart reviews were completed by an independent
research contractor. Data included diagnosis, gender, age,
weight, pre- and post-treatment circumferential limb mea-
surements, pre- and post-treatment patient survey re-
sponses and post-treatment clinical assessment data.
Patient diagnoses were provided by the prescribing
physician.
Data were provided by the treating clinicians via a stan-
dardized clinical assessment form. The form included
assessment of ﬁbrosis/skin hardening, ability to perform
activities of daily living (ADLs) and active range of motion
(AROM). Although these were experienced lymphedema
clinicians, they were provided an illustrated and detailed
“Measurement Guide” for obtaining consistently derived
circumferential limb measurements. Clinicians measured
the limb with the patient standing and bearing weight. The
leg inseam was measured from the bottom of the heel to
the groin. The lower circumference was recorded at the
ankle and then at 10 cm increments from the ankle up to
the groin. Utilizing these measurements, LVs were calcu-
lated using the formula for a truncated cone, V ¼ h
(C2 þ Cc þ c2)/12(p), where V ¼ the volume of the segment
of the limb, C and c are the circumference at each end, and
h is the distance between segments (10 cm).20
482 S.C. Muluk et al.Upon receipt of the APCD, patients received in-home
training on device operation and prescribed treatment
protocol. Patients were advised to remove all static
compression garments, inelastic bandages and/or wraps
prior to device garment application for APCD treatment.
Patients were further advised to reapply their daily gar-
ments/wraps after APCD treatment. Patients were directed
to lie supine during treatment.
The pre- and post-treatment patient survey to evaluate
patient-reported effectiveness and satisfaction of the APCD
treatment consisted of four questions utilizing a Likert-type
scale.
Statistical methods
Analyses were performed on the full cohort of patients and
sub-analyses on unilateral and bilateral lymphedema pa-
tients. Additional analyses were performed on sub-groups
of subjects by lymphedema type.
Continuous variables are described using sample size,
mean, and standard deviation. A two-sided p value of .05Table 1. Baseline demographics and clinical characteristics.
Gender Female
%
Male
%
Age N
Mean  SD
Min, Max
BMIa (M2) N
Mean  SD
Min, Max
Side treated Bilateral
%
Left
%
Right
%
Type of lymphedema Primary
%
Secondary
%
Previous infections Yes
%
No
%
Previous PCD treatment Yes
%
No
%
Duration of diagnosis >5 years
%
2e5 years
%
6 months to 2 years
%
<6 months
%
a p < .0001.was used to determine statistical signiﬁcance for the
rejection of the null hypothesis.
For LV change (LVC), a paired t-test was used to compare
the mean difference between baseline and post-treatment
LVs. Bilateral subjects were analyzed two ways: “Per
Limb” (each limb reported separately) and “Per Subject”
(using the limb with the greater baseline LV).
For LVC from baseline analyses comparing the effect of
treatment between groups, an analysis of covariance
(ANCOVA) was used, where the response variable is post-
treatment LV and the independent variables are baseline
LV and group. An assessment was made of any interaction
between group and baseline LV. If the p value for the
interaction term in the ANCOVA was above .1, the inter-
action term was removed from the analysis.
The relationship between body mass index (BMI) and age
with LVC was evaluated using linear regression, with LVC as
the response variable, using a second degree polynomial ﬁt
on BMI and age, as the independent variables, to allow for
quadratic (curvilinear) relationships to be explored.Total Bilateral Unilateral
131/196 92/136 39/60
66.8 67.6 65.0
65/196 44/136 21/60
33.2 32.4 35.0
196 136 60
55.8  13.3 55.9  13.6 55.6  12.6
14.5, 86.0 14.5, 86.0 17.2, 83.5
191 133 58
38.2  13.2 40.9  13.7 31.9  9.3
18.9, 78.7 18.9, 78.7 19.1, 64.5
136/196 136/136 0/60
69.4 100.0 0.0
31/196 0/136 31/60
15.8 0.0 51.7
29/196 0/136 29/60
14.8 0.0 48.3
41/196 31/136 10/60
20.9 22.8 16.7
155/196 105/136 50/60
79.1 77.2 83.3
75/191 55/132 20/59
39.3 41.7 33.8
116/191 77/132 39/59
60.7 58.3 66.1
46/195 30/135 16/60
23.6 22.2 26.7
149/195 105/135 44/60
76.4 77.8 73.3
51/171 44/121 7/50
29.8 36.4 14.0
31/171 17/121 14/50
18.1 14.0 28.0
39/171 23/121 16/50
22.8 19.0 32.0
50/171 37/121 13/50
29.2 30.6 26.0
Table 2. Treatment program and frequency.
Treatment program
and duration (min)
Bilateral
n ¼ 136
Unilateral
n ¼ 60
L1: Full leg and core
(trunk) (60)
126 55
L1 þ supplement
programa (60 þ 15 to 45)
8 4
L3: Trunk and thigh (30) 2 0
L5: Calf and foot (30) 1 1
Treatment frequency
QD alternating limbs 79 e
QD both limbs 57 e
QD e 56
BID e 4
L1, L3 and L5 correspond to the controller setting on the APCD for
the particular treatment program prescribed.
a Supplemental programs range in duration from 15 to 45 min
each, and are designed to provide focused treatment to a partic-
ular body area/region.
European Journal of Vascular and Endovascular Surgery Volume 46 Issue 4 p. 480e487 October/2013 483Paired comparisons of subject survey responses at
baseline and post-treatment were made using Stuart-
Maxwell Marginal Homogeneity Tests and Wilcoxon
Signed Rank Tests, the latter using numeric rank trans-
formations of the ordinal survey responses. These analyses
were performed on subjects responding to both baseline
and post-treatment surveys.
No imputation of missing data was performed and
individual analyses were only performed on subjects
having required data reported for that particular analysis.
All analyses were performed using R Version 2.15.0 or
greater (R Foundation for Statistical Computing, Vienna,
Austria).Figure 1. Boxplots for multiple patient subsets, displaying paired pre-tr
represents the median value (50th percentile), and the bottom and top
represent the observed group range. All within subset paired comparis
LV than the unilateral patients; however, this difference was not signiﬁc
for each subset (left to right) was: 1,225.8, 811.1, 1,150.4, 1,149.5, 1,RESULTS
Baseline characteristics are reported in Table 1. The cohort
was characterized by more female patients (68%) and in-
dividuals with secondary lymphedema accounted for nearly
80% of the study population. The most frequently docu-
mented secondary causes of lymphedema were CVI (53),
cancer (47), surgery (non-cancer)/trauma (29), infections
(14), and other poorly deﬁned etiologies (12).
The prescribed APCD treatment programs and frequency
of treatment are presented in Table 2.
LV changes from baseline to post-treatment are illus-
trated in the boxplot displayed in Fig. 1. Overall, the study
population demonstrated a mean LV reduction of 8% or
1,149.7 mL (range 12,411.1 to þ3,084.4) (p ¼ <.0001.).
Baseline LV was a strong predictor of the beneﬁcial
response (p < .0001), as patients with larger baseline LV
had greater LV reduction. Bilateral patients experienced a
greater reduction than unilateral patients (representing 9%
and 7% reductions, respectively). However, this difference
was not signiﬁcant after adjusting for baseline LV.
Based on the “per subject” analysis, almost 90% (88%;
n ¼ 173) of patients demonstrated an LV reduction in
response to treatment and 35% demonstrated a substantial
reduction >10% (Fig. 2). Based on the “per limb” approach,
the response distribution was similar (85%; 33%) (Fig. 2). A
minority of patients (n ¼ 23 or 12%) experienced an in-
crease in LV. Four patients experienced a LV increase >10%,
and, of these, two were non-compliant with PCD treatment.
One patient with a >20% LV increase had a long-standing
wound that reduced in size during PCD treatment.
There was no signiﬁcant difference in LV reduction for
bilateral patients treated twice daily versus those treated
once daily on alternating limbs (8.5% vs. 8.4%, p ¼ .93).eatment versus post-treatment limb volume (LV). The mid-box line
of the boxes represent the 25th and 75th percentiles. The whiskers
ons are p < .0001. Bilateral patients achieved a larger reduction in
ant after adjustment of baseline LV. The mean reduction in LV (mL)
038.4, 1,368.4, 655.6 and 864.8, respectively.
Figure 2. Percent change in limb volume (LV) from baseline.
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10%, but the differences among patients with different di-
agnoses was not signiﬁcant.
Patient factors such as age and BMI were also analyzed
for an association with response to APCD treatment (Fig. 3).
Larger BMI was associated with greater reduction in LV
(p < .0001). There was a trend for older patients to have
lesser reduction in LV, but this was not statistically signiﬁ-
cant (p ¼ .29). Similarly, patients with larger baseline LV
had greater reduction. Additional testing with a single in-
dependent variable (either BMI or baseline LV, both again
quadratic) was also done. The R2 for each model
(BMI ¼ .0636, baseline LV ¼ .1820) suggested that while
neither variable accounted for the majority of the variationFigure 3. The relationship between limb volume change (LVC) and
body mass index (BMI). This ﬁgure demonstrates that as BMI in-
creases, limb volume (LV) reduction with advanced pneumatic
compression device (APCD) treatment also increases signiﬁcantly.
As age increases, LVC tends to decline (p ¼ NS).in LV reduction, baseline LV was a more important predictor
of response.Post treatment patient survey and satisfaction
The post treatment survey, consisting of four questions
utilizing a ﬁve-point Likert scale, was completed by 98 pa-
tients yielding a 50% completion rate. Patients demon-
strated consistent improvement in response to treatment,
with three of four questions showing a statistically signiﬁ-
cant positive category shift (Fig. 4). Patients reported an
increased ability to control lymphedema through APCD
treatment at home. Patients also reported an increased
ability to perform ADLs and a reduction in the frequency of
pain with ADLs. Sixty-six percent of survey responders
indicated they were “Very Satisﬁed” overall with APCD
treatment, and another 30% (n ¼ 29) indicated they were
“Satisﬁed”.
To address the possibility of a survey response bias, a
responder analysis was completed. LVC for patients
that returned the survey (response) was compared with
that for patients who did not return the survey (non-
response). The response group had a reduction of 8% or
1,049.7 mL (range 10,433.5 to þ2,328.4), whereas the
non-response group had a reduction of 9% or 1,242.1 mL
(range 12,411.1 to þ3,084.4). Thus, patients with large LV
reduction were not over-represented among the survey
responders. Other patient characteristics (age, gender) were
also similar between the two groups.Clinician assessment
In 86% (n ¼ 168) of the patients, a reduction in skin
hardening or ﬁbrosis was reported based on manual
assessment of skin pliability and tethering. Based on clinical
observation of function, nearly all (85%; n ¼ 165) patients
demonstrated an increased ability to perform ADLs; a high
fraction (77%, n ¼ 149) also demonstrated increased
AROM.
Adverse events. Four adverse events (AEs) were recorded
for these subjects. Two events were likely related to device
treatment: one patient experienced muscle cramps and a
second reported increased limb erythema. The other two
events were unlikely to be related to device treatment and
included a non-speciﬁc allergic reaction and increased fa-
tigue. All AEs resolved, and patients continued to use the
APCD.DISCUSSION
Prevalence and impact of LE lymphedema are high, but
large studies of the response of this condition to
compressive therapies are few. The current study repre-
sents, to our knowledge, the largest study of PCD outcomes
in LE patients. These data demonstrate that APCD use is
associated with a mean LV reduction of 1,149.7 mL or 8%,
and this reduction was consistently achieved across the
treatment cohort (only 12% of patients did not demonstrate
Figure 4. Pre- and post-advanced pneumatic compression device
(APCD) treatment patient survey questions and results.
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improvement in QOL and no signiﬁcant adverse effects.
The magnitude of response observed in this study cannot
be readily compared with previous LE lymphedema studies,
because these older studies reported limb diameters at
various anatomic landmarks, making it difﬁcult to calculate
LVs.7,8,13 LV reduction data are more readily available for UE
patients. In a systematic review, Moseley21 found average
LV reduction of 26% across several studies after PCD ther-
apy; however, because of large differences in muscle and
bone mass, the fractional LV reduction that can be achieved
is likely to be different for arms and legs.
Objective evaluation of PCDs has been suboptimal,
contributing to an environment in which the opinion of
experienced clinicians is substituted for high-quality data.
Most studies have examined UE BCRL. One randomized
post-mastectomy study of 80 patients showed no beneﬁt
from PCD treatment.11 Another randomized study of 27
BCRL patients found that PCD therapy had beneﬁt when
used adjunctively to CDT.10 A pilot study of BCRL patients
found that PCD treatment utilizing the same device as the
current study was more effective in reducing arm volume
and patient weight than self-administered MLD.14 In a
single-arm study of 25 patients (7 UE; 18 LE), Richmand
reported signiﬁcant LV reduction with short-term, in-hos-
pital PCD use.13 The same group studied 49 patients over a
longer term (mean 25 months) and found that 36 patients
maintained either full- or partial-response.8
Evaluation of published data is also challenged by the
high inter-study variability of types of PCDs. Early single-
chambered sleeves with simple controllers have been
largely replaced by more sophisticated multi-chamber de-
vices, which have varying degrees of programmability for
the amount and timing of pressure in each chamber. Most
PCDs employ a simple concept of ‘milking’ the limb (i.e.,
they generate higher pressures distally and progressively
lower pressures proximally). These devices typically
generate relatively high static pressures of 30e60 mmHg in
the UE and 80e110 mmHg in the LE.22,23 The PCD used in
this study provides a more complex sequence of dynamic
pressurization designed to mimic MLD, including a chamber
inﬂation pattern designed to replicate the “work and
release” and “hand-over-hand” manual techniques. It gen-
erates a substantially different pressure proﬁle with appli-
cation of mild, directional and variable pressure followed by
an immediate release of pressure.22 This mechanism is
intended to facilitate the collection and re-absorption of
lymph ﬂuid, much like MLD. Another feature intended to
simulate MLD efﬁcacy is the option to treat the lower
abdomen, a component absent from most PCDs.
This study demonstrates that neither age nor etiology of
lymphedema was a predictor of treatment-related LV
reduction. Larger BMI and larger baseline LV were strong
predictors of LV reduction. As one would expect, these two
parameters are not independent. However, the impact of an
increased baseline LV was stronger than the effect of BMI.
Thus, the most severely affected patients with lymphedema
can anticipate the best treatment efﬁcacy.
486 S.C. Muluk et al.Although LV reduction is an important objective goal of
lymphedema therapy, it is also critical that this reduction be
associated with improvement in patient-reported out-
comes. A small LV reduction can result in a large improve-
ment in function, thus improving QOL.16 Conversely,
patients may remain symptomatic despite experiencing
signiﬁcant reductions in LV. The current study demonstrated
a signiﬁcant positive impact of APCD treatment on function
and pain components of QOL, as demonstrated by a cate-
gory shift in three of the four questions that pertained to
control in managing lymphedema at home.
Our study suggests that home treatment with an APCD
resulting in a mean LV reduction of 8% provides clinically
meaningful impact for the patient. This ﬁnding is supported
by the work of Cormier and colleagues who concluded that
LVC as minimal as 5% had a clinically signiﬁcant impact on
signs and symptoms23 including tenderness, tightness,
heaviness, and pain. The Cormier study included only UE
patients, so inferences regarding patients with LE lymphe-
dema are limited. It is possible that a minimal LV reduction
for LE patients would provide a large QOL impact, as the
legs sustain balance and mobility, facilitating functional in-
dependence. Another study found that patients with LE
lymphedema had signiﬁcantly greater improvement in QOL
scores compared with UE patients after CDT (p ¼ .02).24
There was no correlation between the magnitude of
edema reduction and the post-treatment QOL improve-
ment, indicating that there are other beneﬁts to treatment
than LV reduction alone.
The current study also measured clinician assessment of
tissue ﬁbrosis, ability to perform ADLs, and AROM. These
data showed high rates (77e86%) of favorable responses
for these outcomes, suggesting that APCD treatment
demonstrated therapeutic value beyond LV reduction.
This study has signiﬁcant limitations. Although data were
collected prospectively, registries can never fully represent
the population, including individuals with barriers to care.
This registry report also lacks comparative effectiveness
data. Other lymphedema treatment components were not
standardized. LV measurements were done at variable time
points after initiation of therapy (60  28 days). The study
did not include every patient who may have been treated
with this device, and half of the patients did not give post-
treatment responses to the survey. However, as survey re-
sponders and non-responders had very similar demographic
characteristics and degrees of LV reduction, this bias may be
minimal. Despite these limitations, the data reﬂect a “real
world” experience, which showed statistically signiﬁcant
and clinically meaningful response to APCD therapy in a
large cohort.CONCLUSION
The study demonstrates that APCD treatment can reduce
LV, improve pain, and enhance ability to complete ADLs.
Thus, patients with LE lymphedema enjoyed an improved
QOL. Although these data conﬁrm that clinical beneﬁt is
consistently achieved in real world settings, additionalprospective research would help deﬁne predictors of
improved treatment success, as well as the health economic
impact of such treatment.FUNDING
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